Work

Modulation of tumor associated macrophages enhances oncolytic herpes virotherapy in preclinical models of Ewing sarcoma

Year: 2018
Type: article
Abstract: Ewing sarcoma is a highly aggressive bone and soft tissue cancer that is found predominantly in adolescents and young adults.The aggressive progression of Ewing sarcoma is due in part to the infiltration and activation of pro-tumor M2-like macrophages.Within the traditional classifications of inflammatory M1-like macrophages and immune suppressive M2-like macrophages is a broad panel of noncanonical macrophage subtypes whose actions in tumor progression and tumor resistance to immunotherapy are unknown.Oncolytic virotherapy that selectively replicates in and destroys cancer cells is a promising option for treating Ewing sarcoma through both direct infection of the cancer cells and activation of the host antitumor immune response.The effect of M1-like and M2-like tumor macrophages on oncolytic virus therapy, however, is variable among solid tumors and is unknown in Ewing sarcoma.We observed high activity of M2-like macrophage subtypes M(IL4) and M(IL10) in Ewing sarcoma xenograft models that experience a macrophage-dependent restriction of oncolytic virus antitumor efficacy.Macrophage depletion with Clodrosome or trabectedin greatly enhanced oncolytic virus antitumor efficacy of Ewing sarcoma xenografts by increasing tumor stroma inflammatory activity and decreasing angiogenic and immune suppressive signaling molecules.Our data suggest that combination of trabectedin and oncolytic virus therapy warrants testing in the clinical setting of pediatric sarcoma treatment.The presence of M(IL4) and M(IL10) tumor macrophages may be a cellular iii biomarker for determining antitumor efficacy of trabectedin and oncolytic virus combination therapy in a wider panel of solid tumor types.iv
Author: Denton, Nicholas Lee, Denton
Language: English
Subfield: Immunology
Open Access status: green
OpenAlex ID: W6992918833
FWCI:
Cites: 104
Cited by:
Related to: 9